Working… Menu

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03486301
Recruitment Status : Recruiting
First Posted : April 3, 2018
Last Update Posted : September 30, 2021
Seven and Eight Biopharmaceuticals Inc
Information provided by (Responsible Party):
Birdie Biopharmaceuticals HK Limited

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022